Vistagen Therapeutics Inc (VTGN)

$0.25 +0.00 (1.66%)
Market Cap 9.89M
Revenue (ttm) 1.27M
Net Income (ttm) -69.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,487.40%
Debt to Equity Ratio 0.00
Volume 895,600
Avg Vol 2,300,580
Day's Range N/A - N/A
Shares Out 41.03M
Stochastic %K 74%
Beta 0.40
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical tria...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
marketCaptain
marketCaptain Aug. 4 at 2:40 PM
$VTGN Volume already exceeds the pal 3 drop 🫪🤯
0 · Reply
tommiemac
tommiemac Aug. 4 at 2:37 PM
$VTGN bought setting up nice
0 · Reply
mikethemage
mikethemage Aug. 4 at 2:37 PM
$VTGN buy the dip
0 · Reply
Timing101
Timing101 Aug. 4 at 2:35 PM
$VTGN CRAZY , with the connection to $SRXH news this Morning. I MEAN CRAZY in Volume at over 90 Million Shares traded and OVER 130,000 Trades JUST IN THE FIRST HOUR ! Folks this is a LOW FLOATER , with no where close to this volume, watch it LOCK UP! https://elite.finviz.com/news/376434/srx-global-acquires-stake-in-vistagen-therapeutics-nasdaq-vtgn
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 4 at 2:33 PM
$VTGN
0 · Reply
BlazeofFury
BlazeofFury Aug. 4 at 2:32 PM
Breakout starting on ticker VGAS. dont miss out bulls. Good day on $VTGN $SKYQ
0 · Reply
Bengobingo
Bengobingo Aug. 4 at 2:31 PM
$VTGN Possible #GammaSqueeze Buy calls!
0 · Reply
ACInvestorBlog
ACInvestorBlog Aug. 4 at 2:30 PM
$VTGN into the gap on heavy volume
0 · Reply
mikethemage
mikethemage Aug. 4 at 2:23 PM
$VTGN wheeeeeee
0 · Reply
pakman197
pakman197 Aug. 4 at 2:18 PM
$VTGN Cmon hot double Three's... (to start)!
0 · Reply
Latest News on VTGN
SRX Global acquires stake in Vistagen

2026-08-04T09:10:51.000Z - 5 hours ago

SRX Global acquires stake in Vistagen

SRXH

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Jul 31, 2026, 8:30 AM EDT - 4 days ago

Vistagen Appoints Douglas J. Williamson to its Board of Directors

DRUG

Vistagen Therapeutics Proxy statement: Proxy filing

Jul 31, 2026, 8:00 AM EDT - 4 days ago

Vistagen Therapeutics Proxy statement: Proxy filing

Vistagen Therapeutics Proxy statement: Proxy filing

Jul 31, 2026, 8:00 AM EDT - 4 days ago

Vistagen Therapeutics Proxy statement: Proxy filing

Vistagen Therapeutics Transcript: Study update

Jun 30, 2026, 8:30 AM EDT - 5 weeks ago

Vistagen Therapeutics Transcript: Study update

Vistagen Therapeutics Press release: Study update

Jun 30, 2026, 8:30 AM EDT - 5 weeks ago

Vistagen Therapeutics Press release: Study update

Vistagen announces fasedienol did not achieve primary endpoint

2026-06-30T12:05:47.000Z - 5 weeks ago

Vistagen announces fasedienol did not achieve primary endpoint

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Jun 30, 2026, 8:00 AM EDT - 5 weeks ago

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Jun 15, 2026, 4:30 PM EDT - 7 weeks ago

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Vistagen Therapeutics Earnings release: Q4 2026

Jun 15, 2026, 4:00 PM EDT - 7 weeks ago

Vistagen Therapeutics Earnings release: Q4 2026

Vistagen Therapeutics Annual report: Q4 2026

Jun 15, 2026, 4:00 PM EDT - 7 weeks ago

Vistagen Therapeutics Annual report: Q4 2026

Vistagen announces fasedienol achieves minimum patient exposures

2026-06-09T12:37:17.000Z - 2 months ago

Vistagen announces fasedienol achieves minimum patient exposures

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Jun 9, 2026, 8:30 AM EDT - 2 months ago

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 27, 2026, 8:30 AM EDT - 2 months ago

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 2:35 PM EDT - 2 months ago

Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Vistagen appoints Angelov as Chief Medical Officer

2026-05-19T12:37:06.000Z - 2 months ago

Vistagen appoints Angelov as Chief Medical Officer

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19, 2026, 8:30 AM EDT - 2 months ago

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

MD

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 14, 2026, 8:30 AM EDT - 2 months ago

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Vistagen reports preliminary positive data on ongoing PALISADE-3 study

2026-05-12T11:52:14.000Z - 3 months ago

Vistagen reports preliminary positive data on ongoing PALISADE-3 study

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 12, 2026, 7:30 AM EDT - 3 months ago

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen announces completion of last patient visit in PALISADE-4 study

2026-05-08T12:22:06.000Z - 3 months ago

Vistagen announces completion of last patient visit in PALISADE-4 study

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

May 8, 2026, 7:30 AM EDT - 3 months ago

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

AbCellera target is profile more attractive than Vistagen, says JonesResearch

2026-04-22T14:45:36.000Z - 3 months ago

AbCellera target is profile more attractive than Vistagen, says JonesResearch

ABCL

Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing

2026-04-22T13:41:58.000Z - 3 months ago

Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Apr 22, 2026, 8:30 AM EDT - 3 months ago

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 9:00 AM EDT - 5 months ago

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Vistagen to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:30 AM EST - 5 months ago

Vistagen to Participate in Upcoming Investor Conferences

Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:50 PM EST - 5 months ago

Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims

2026-02-25T17:53:19.000Z - 5 months ago

Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 5 months ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Feb 12, 2026, 5:00 PM EST - 6 months ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Vistagen Therapeutics Quarterly report: Q3 2026

Feb 12, 2026, 5:00 PM EST - 6 months ago

Vistagen Therapeutics Quarterly report: Q3 2026

Vistagen Therapeutics Earnings release: Q3 2026

Feb 12, 2026, 5:00 PM EST - 6 months ago

Vistagen Therapeutics Earnings release: Q3 2026

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 12, 2026, 4:30 PM EST - 6 months ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 6, 2026, 9:52 AM EST - 6 months ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Feb 4, 2026, 8:30 AM EST - 6 months ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 22, 2026, 10:45 AM EST - 6 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jan 16, 2026, 5:06 PM EST - 7 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Vistagen downgraded to Hold from Buy at Jefferies

2025-12-17T19:25:24.000Z - 8 months ago

Vistagen downgraded to Hold from Buy at Jefferies

Vistagen downgraded to Hold at Jefferies after social anxiety study miss

2025-12-17T19:25:11.000Z - 8 months ago

Vistagen downgraded to Hold at Jefferies after social anxiety study miss

Vistagen downgraded to Hold from Buy at Maxim

2025-12-17T17:20:14.000Z - 8 months ago

Vistagen downgraded to Hold from Buy at Maxim

Vistagen downgraded to Market Perform from Outperform at William Blair

2025-12-17T16:35:29.000Z - 8 months ago

Vistagen downgraded to Market Perform from Outperform at William Blair

Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss

2025-12-17T16:35:21.000Z - 8 months ago

Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

2025-12-17T15:50:39.000Z - 8 months ago

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

Vistagen downgraded to Hold from Buy at Stifel

2025-12-17T15:45:17.000Z - 8 months ago

Vistagen downgraded to Hold from Buy at Stifel

Vistagen downgraded to Neutral from Buy at Lucid Capital

2025-12-17T14:40:46.000Z - 8 months ago

Vistagen downgraded to Neutral from Buy at Lucid Capital

Vistagen SAD study did not achieve primary endpoint

2025-12-17T14:05:58.000Z - 8 months ago

Vistagen SAD study did not achieve primary endpoint

VistaGen Therapeutics trading resumes

2025-12-17T13:55:10.000Z - 8 months ago

VistaGen Therapeutics trading resumes

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 8 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 8 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 8 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Nov 13, 2025, 5:00 PM EST - 9 months ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Vistagen Therapeutics Quarterly report: Q2 2026

Nov 13, 2025, 5:00 PM EST - 9 months ago

Vistagen Therapeutics Quarterly report: Q2 2026

Vistagen Therapeutics Earnings release: Q2 2026

Nov 13, 2025, 5:00 PM EST - 9 months ago

Vistagen Therapeutics Earnings release: Q2 2026

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 9 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 3:20 PM EST - 9 months ago

Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 9 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 9 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 18, 2025, 2:20 PM EDT - 11 months ago

Vistagen Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics Transcript: AGM 2025

Sep 9, 2025, 12:00 PM EDT - 11 months ago

Vistagen Therapeutics Transcript: AGM 2025

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Vistagen Therapeutics Quarterly report: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Quarterly report: Q1 2026

Vistagen Therapeutics Earnings release: Q1 2026

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q1 2026

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing

Vistagen Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Vistagen Therapeutics Proxy statement: Proxy Filing

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 1 year ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Vistagen Therapeutics Earnings release: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings release: Q4 2025

Vistagen Therapeutics Annual report: Q4 2025

Jun 17, 2025, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Annual report: Q4 2025

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

marketCaptain
marketCaptain Aug. 4 at 2:40 PM
$VTGN Volume already exceeds the pal 3 drop 🫪🤯
0 · Reply
tommiemac
tommiemac Aug. 4 at 2:37 PM
$VTGN bought setting up nice
0 · Reply
mikethemage
mikethemage Aug. 4 at 2:37 PM
$VTGN buy the dip
0 · Reply
Timing101
Timing101 Aug. 4 at 2:35 PM
$VTGN CRAZY , with the connection to $SRXH news this Morning. I MEAN CRAZY in Volume at over 90 Million Shares traded and OVER 130,000 Trades JUST IN THE FIRST HOUR ! Folks this is a LOW FLOATER , with no where close to this volume, watch it LOCK UP! https://elite.finviz.com/news/376434/srx-global-acquires-stake-in-vistagen-therapeutics-nasdaq-vtgn
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 4 at 2:33 PM
$VTGN
0 · Reply
BlazeofFury
BlazeofFury Aug. 4 at 2:32 PM
Breakout starting on ticker VGAS. dont miss out bulls. Good day on $VTGN $SKYQ
0 · Reply
Bengobingo
Bengobingo Aug. 4 at 2:31 PM
$VTGN Possible #GammaSqueeze Buy calls!
0 · Reply
ACInvestorBlog
ACInvestorBlog Aug. 4 at 2:30 PM
$VTGN into the gap on heavy volume
0 · Reply
mikethemage
mikethemage Aug. 4 at 2:23 PM
$VTGN wheeeeeee
0 · Reply
pakman197
pakman197 Aug. 4 at 2:18 PM
$VTGN Cmon hot double Three's... (to start)!
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Aug. 4 at 2:13 PM
$VTGN Insane volume. Round 2 possible like $ADGM
0 · Reply
mikethemage
mikethemage Aug. 4 at 2:12 PM
$VTGN holding this till .50
0 · Reply
Dirt_Nap_Dead
Dirt_Nap_Dead Aug. 4 at 2:07 PM
$SRXH I believe people that have been in $VTGN and $SMTK see that Eric has bought into those companies.....and they want out knowing that anything Eric touches turns to shit. Run for your lives!!!!
0 · Reply
Timing101
Timing101 Aug. 4 at 2:03 PM
$SRXH Well, Positive Elements One must say that $SRXH has going for it is the GROWTH OF THE PORTFOLIO Continues to GROW. Plus the Portfolio of ASSETS is Really Quite Diverse. This addition today of $VTGN (all ready added to mine up over 10%) is Great. https://elite.finviz.com/news/376434/srx-global-acquires-stake-in-vistagen-therapeutics-nasdaq-vtgn
1 · Reply
mikethemage
mikethemage Aug. 4 at 2:01 PM
$VTGN looks more like sideways then up
0 · Reply
mikethemage
mikethemage Aug. 4 at 1:59 PM
$VTGN can this just go to .50 like today?
0 · Reply
Bengobingo
Bengobingo Aug. 4 at 1:55 PM
$VTGN We are on Robinhood daily price jump page and trending North! 🪐
0 · Reply
joe77w
joe77w Aug. 4 at 1:55 PM
$VTGN incredible volumes
0 · Reply
sireofbeef
sireofbeef Aug. 4 at 1:54 PM
$SRXH threw some dividend at $VTGN 👍
0 · Reply
MikeScottTradingCo
MikeScottTradingCo Aug. 4 at 1:54 PM
$VTGN we’ve traded nearly 2x the float.. consolidation will happen. Extension for compliance granted. Another slight pop then consolidation.. new director company PR with earnings.. pump back over 1.00 to regain compliance… road map is here
1 · Reply
Bengobingo
Bengobingo Aug. 4 at 1:52 PM
$VTGN ITS STILL EARLY! 💎💪🌕
0 · Reply
defineme44
defineme44 Aug. 4 at 1:49 PM
$VTGN adding calls .50 🚀🚀🚀
0 · Reply